These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

328 related items for PubMed ID: 27050071

  • 1. TR4 nuclear receptor enhances the cisplatin chemo-sensitivity via altering the ATF3 expression to better suppress HCC cell growth.
    Shen J, Lin H, Li G, Jin RA, Shi L, Chen M, Chang C, Cai X.
    Oncotarget; 2016 May 31; 7(22):32088-99. PubMed ID: 27050071
    [Abstract] [Full Text] [Related]

  • 2. TR4 nuclear receptor suppresses HCC cell invasion via downregulating the EphA2 expression.
    Jin R, Lin H, Li G, Xu J, Shi L, Chang C, Cai X.
    Cell Death Dis; 2018 Feb 15; 9(3):283. PubMed ID: 29449527
    [Abstract] [Full Text] [Related]

  • 3. Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals.
    Shi L, Lin H, Li G, Sun Y, Shen J, Xu J, Lin C, Yeh S, Cai X, Chang C.
    Cancer Lett; 2016 Apr 01; 373(1):45-56. PubMed ID: 26805759
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Downregulation of miR-33a-5p in Hepatocellular Carcinoma: A Possible Mechanism for Chemotherapy Resistance.
    Meng W, Tai Y, Zhao H, Fu B, Zhang T, Liu W, Li H, Yang Y, Zhang Q, Feng Y, Chen G.
    Med Sci Monit; 2017 Mar 14; 23():1295-1304. PubMed ID: 28291769
    [Abstract] [Full Text] [Related]

  • 6. Knockdown of THOC1 reduces the proliferation of hepatocellular carcinoma and increases the sensitivity to cisplatin.
    Cai S, Bai Y, Wang H, Zhao Z, Ding X, Zhang H, Zhang X, Liu Y, Jia Y, Li Y, Chen S, Zhou H, Liu H, Yang C, Sun T.
    J Exp Clin Cancer Res; 2020 Jul 15; 39(1):135. PubMed ID: 32669125
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice.
    Chen X, Wang Y, Tao J, Shi Y, Gai X, Huang F, Ma Q, Zhou Z, Chen H, Zhang H, Liu Z, Sun Q, Peng H, Chen R, Jing Y, Yang H, Mao Y, Zhang H.
    Gastroenterology; 2015 Sep 15; 149(3):741-52.e14. PubMed ID: 25980751
    [Abstract] [Full Text] [Related]

  • 15. Brusatol induces ferroptosis to inhibit hepatocellular carcinoma progression by targeting ATF3.
    Wan Y, Cheng J, Gan D, He J, Chen A, Ma J, Li Y, Wang X, Ran J, Chen D, Li J.
    Chem Biol Drug Des; 2024 Jun 15; 103(6):e14565. PubMed ID: 38862254
    [Abstract] [Full Text] [Related]

  • 16. Osteopontin induces autophagy to promote chemo-resistance in human hepatocellular carcinoma cells.
    Liu G, Fan X, Tang M, Chen R, Wang H, Jia R, Zhou X, Jing W, Wang H, Yang Y, Yin F, Wei H, Li B, Zhao J.
    Cancer Lett; 2016 Dec 28; 383(2):171-182. PubMed ID: 27702661
    [Abstract] [Full Text] [Related]

  • 17. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
    Ma L, Li G, Zhu H, Dong X, Zhao D, Jiang X, Li J, Qiao H, Ni S, Sun X.
    Cancer Lett; 2014 Dec 01; 355(1):96-105. PubMed ID: 25218350
    [Abstract] [Full Text] [Related]

  • 18. ψ-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling.
    Ding J, Wen W, Xiang D, Yin P, Liu Y, Liu C, He G, Cheng Z, Yin J, Sheng C, Zhang W, Nan F, Ye W, Zhang X, Wang H.
    Oncotarget; 2015 May 10; 6(13):11627-39. PubMed ID: 25890498
    [Abstract] [Full Text] [Related]

  • 19. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
    Ma L, Wang X, Jia T, Wei W, Chua MS, So S.
    Oncotarget; 2015 Sep 22; 6(28):25390-401. PubMed ID: 26246473
    [Abstract] [Full Text] [Related]

  • 20. Induction of IL-6Rα by ATF3 enhances IL-6 mediated sorafenib and regorafenib resistance in hepatocellular carcinoma.
    Dai Z, Wang X, Peng R, Zhang B, Han Q, Lin J, Wang J, Lin J, Jiang M, Liu H, Lee TH, Lu KP, Zheng M.
    Cancer Lett; 2022 Jan 01; 524():161-171. PubMed ID: 34687791
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.